Compare ING Groep NV (ING) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Tango Therapeutics Inc. — how do they compare? ING Groep NV trades at $33.34 (market cap $95.72B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: ING Groep NV is far larger — about 25.6× Tango Therapeutics Inc.'s market cap, and ING Groep NV pays a 3.95% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 94 Days and Tango Therapeutics Inc. for 0 Days on average.
| ING | TNGX | |
|---|---|---|
Market Cap | $95.72B | $3.74B |
Volume | 2,335,394 | 3,438,781 |
Sector | Financials | Health |
52-Week High | $37.27 | $32.90 |
52-Week Low | $23.66 | $7.50 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $235.88B | $2.76B |
Dividend Yield | 3.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $33.63, up 0.72% today, with a bearish technical signal but strong fundamentals including a 28.34% net income margin and consistent earnings beats. Recent news highlights management's raised ROE target above 16% for 2027, driven by revenue growth and AI initiatives. Cash flow trends show volatile net outflows, with 2025 net cash flow at -$14.92 billion.
The outlook is mixed: analyst consensus is bullish with 65% buy ratings, but technical indicators and cash flow volatility pose risks. Upside potential hinges on execution of growth strategies and cost discipline, while regulatory scrutiny and macroeconomic pressures remain key watchpoints for investors.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
